Patients with upper-quarter Pten protein level showed significantly shorter median survival and higher HR compared to the others, and this association was evident for both OS

and DFS (P < .05, Cox regression). To our knowledge, this study presents the first analysis on the prognostic value of quanti- fied Pten protein level for survival of patients with GBM. Meanwhile, it should be noted that PTEN mRNA level and promoter methylation were not associated with survival of patients with GBM, and this may explain why previous studies focusing on mRNA or methylation did not report any prognostic significance [26]. Interestingly, GBM with increased Pten protein level displayed substantial alterations in signal- ing pathways involved in DNA damage, MAPK cascade, and cell apoptotic process, which may provide mechanistic explanations for the chemoresistant phenotype and worse prognosis of these patients. see more The distinct effects of nonsense and missense mutations of the PTEN gene also add to the complexity of mutational effects of this pivotal tumor suppressor. Nonsense mutations, but not missense or frameshift mutations, were associated with shorter DFS of patients with GBM (median survival time

decreased by approximately 50%). Consistently, only nonsense mutations were correlated to the signifi- cant increase of mutations in the genome and the potent decrease in p53 and Gata3 protein levels. These findings suggest stronger LOF effects for nonsense mutations and lead to the question whether mutations of PTEN should be equally considered when evaluating their biologic consequences selleckchem or prognostic significances. In fact, distinct mutational effects have been well characterized for another important tumor suppressor, p53. Hot-spot mutations of p53 confer distinct effects on tumor spectrum and survival of mutant knock-in mouse models [27], [28] and [29], and these are considered

as consequences of different LOF and GOF effects [30] and [31]. To determine if PTEN mutations also display different strengths of LOF or even GOF effects, both in vitro and in vivo studies should be carried out on the basis of each frequently Edoxaban occurring mutation. Finally, we show that the survival-shortening PTEN nonsense mutations can be targeted by drugs that inhibit PKC (bryostatin) and Raf (AZ628) or activate procaspase 3 (PAC_1). These findings suggest a link between PTEN genotype and drug sensitivity profile and encourage future studies employing PTEN status as a marker for GBM subclassification and personalized therapeutics. “
“Melanoma is a highly aggressive neoplasm. Patients with distant metastases often face very poor prognosis, with a median survival rate of approximately 9 months, and with less than 10% of patients surviving beyond 5 years [1] and [2]. Tumor growth and spread is known to be regulated by the crosstalk between tumor cells and stroma including immune cells.